Tiffany P Quock1, Tingjian Yan2, Eunice Chang2, Spencer Guthrie3, Michael S Broder2. 1. Prothena Biosciences Inc, 331 Oyster Point Boulevard; South San Francisco, CA 94080, USA. 2. Partnership for Health Analytic Research, LLC, 280 S. Beverly Dr. Ste. 404, Beverly Hills, CA 90212, USA. 3. Biopharma Strategic Consulting, LLC, 208 2nd Ave, San Francisco, CA 94118, USA.
Abstract
AIM: To estimate healthcare utilization and costs in amyloid light-chain (AL) amyloidosis. PATIENTS & METHODS: AL amyloidosis patients were identified in 2007-2015 claims databases if they had ≥1 inpatient/≥2 outpatient claims consistent with AL amyloidosis and received ≥1 AL-specific treatment. Descriptive statistics were reported. RESULTS: 50.1% (n = 3670) were admitted ≥1 time during the year, 11.3% (n = 827) ≥3 times. From 2007 to 2015, bortezomib use increased from 4.6 to 25.3%; melphalan use decreased from 18.9 to 2.0%; costs increased from 92,866 to $114,030. Among incident patients with at least 2 years of follow-up, healthcare utilization and costs decreased from first to second year post-diagnosis. CONCLUSION: AL chemotherapy-based prescribing practices changed. Total annual healthcare costs increased over time among AL amyloidosis patients.
AIM: To estimate healthcare utilization and costs in amyloid light-chain (AL) amyloidosis. PATIENTS & METHODS:AL amyloidosispatients were identified in 2007-2015 claims databases if they had ≥1 inpatient/≥2 outpatient claims consistent with AL amyloidosis and received ≥1 AL-specific treatment. Descriptive statistics were reported. RESULTS: 50.1% (n = 3670) were admitted ≥1 time during the year, 11.3% (n = 827) ≥3 times. From 2007 to 2015, bortezomib use increased from 4.6 to 25.3%; melphalan use decreased from 18.9 to 2.0%; costs increased from 92,866 to $114,030. Among incident patients with at least 2 years of follow-up, healthcare utilization and costs decreased from first to second year post-diagnosis. CONCLUSION:AL chemotherapy-based prescribing practices changed. Total annual healthcare costs increased over time among AL amyloidosispatients.
Entities:
Keywords:
AL amyloidosis; healthcare costs; healthcare resource utilization
Authors: Shawna A Cooper; Christopher J Dick; Pinaki Misra; Nelson Leung; Carrie A Schinstock; Marina Ramirez-Alvarado Journal: Front Oncol Date: 2022-10-04 Impact factor: 5.738